Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...

Eli Lilly on Thursday reported promising results for a daily pill that could serve as an alternative to injectable ...

Since I downgraded the stock, shares have seen upside of only 0.2%. That compares to the 1 ... Eli Lilly has a bright future ahead. Having said that, such a high-quality company demands a high ...

Doctors field hundreds of calls about Mounjaro availability Patients now have alternatives to overseas, black market Entry gives Lilly edge ... a list price of $1,079.77 a month in the U.S ...

In an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds.

Eli Lilly's oral GLP-1 drug orforglipron met key Phase 3 goals in type 2 diabetes, lowering A1C and weight with a favorable ...

Eli Lilly (NYSE:LLY) underwent analysis by 7 analysts ... Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $1034.0, along with a high ...

Shares in pharmaceuticals firm Eli Lilly (LLY) ballooned higher today after revealing its new needle-free weight loss drug had performed ...